Advanced search    

Search: authors:"Andrea Rubbert-Roth"

5 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases

(Yardley, PA, USA). Support for this assistance was funded by F. Hoffmann–La Roche, Basel, Switzerland. Disclosures. Andrea Rubbert-Roth reports honoraria and advisory board fees from Roche and honoraria

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

Corresponding author: Andrea Rubbert-Roth 0 Division of Rheumatology, Department of Internal Medicine, University Hospital of Geneva , 26 Avenue Beau-Sejour, 1211 Geneva 14 , Switzerland 1

Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients

Joerg Wendler 0 Gerd R Burmester Helmut Srensen Andreas Krause Constanze Richter Hans-Peter Tony Andrea Rubbert-Roth Peter Bartz-Bazzanella Siegfried Wassenberg Iris Haug-Rost Thomas Drner 0

Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases

tocilizumab. Matthias Laudes and Andrea Rubbert-Roth received lecture fees from the same company. The company does not alter the adherence to all the PLoS ONE policies on sharing data and material. The

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Introduction Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology...